Key Points
- EVP Corey Manley sold 7,405 shares on March 16 at an average price of $34.69 for $256,879.45, reducing his holding by 7.11% to 96,717 shares valued at about $3.36 million.
- Omnicell reported Q4 EPS of $0.40, missing the $0.47 consensus while revenue was $313.98 million, and issued Q1 2026 guidance of $0.26–$0.36 and FY2026 guidance of $1.65–$1.85.
- Shares trade near $35 with a market cap of $1.59 billion and an elevated P/E of 877.47; analysts' consensus is a “Moderate Buy” with a $55.29 average price target.
Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) EVP Corey Manley sold 7,405 shares of the business's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the transaction, the executive vice president directly owned 96,717 shares in the company, valued at $3,355,112.73. This trade represents a 7.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Omnicell Stock Up 2.3%
Shares of OMCL opened at $35.09 on Wednesday. The company has a 50-day simple moving average of $43.27 and a 200-day simple moving average of $38.53. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43. The firm has a market capitalization of $1.59 billion, a P/E ratio of 877.47, a P/E/G ratio of 1.23 and a beta of 0.79. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.00.
Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing analysts' consensus estimates of $0.47 by ($0.07). The firm had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.Omnicell's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new stake in Omnicell during the 2nd quarter worth about $26,000. First Horizon Corp bought a new position in shares of Omnicell in the third quarter worth about $31,000. Farther Finance Advisors LLC raised its stake in shares of Omnicell by 784.8% in the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company's stock worth $36,000 after acquiring an additional 1,036 shares during the last quarter. Clearstead Advisors LLC lifted its position in shares of Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company's stock worth $56,000 after purchasing an additional 1,218 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Omnicell during the fourth quarter worth approximately $58,000. Institutional investors and hedge funds own 97.70% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently weighed in on OMCL shares. Piper Sandler reiterated an "overweight" rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Weiss Ratings lowered shares of Omnicell from a "hold (c-)" rating to a "sell (d)" rating in a research report on Monday, March 2nd. Zacks Research upgraded shares of Omnicell from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 10th. Wells Fargo & Company upped their price objective on Omnicell from $43.00 to $52.00 and gave the company an "overweight" rating in a research note on Monday, January 5th. Finally, KeyCorp raised Omnicell from a "sector weight" rating to an "overweight" rating and set a $60.00 target price for the company in a report on Wednesday, January 7th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.29.
Get Our Latest Stock Report on OMCL
About Omnicell
(
Get Free Report)
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
